Bristol Myers Squibb Reports VALOR-HCM Trial Results for Camzyos in Hypertrophic Cardiomyopathy

Bristol Myers Squibb today announced results from the Phase 3 VALOR-HCM trial evaluating Camzyos (mavacamten) in patients with symptomatic obstructive hypertrophic cardiomyopathy (HCM) who were eligible for septal reduction therapy. The trial demonstrated that significantly fewer patients treated with Camzyos met the criteria for septal reduction therapy at week 16 compared to placebo.